Failure of Novartis Lp(a) drug raises questions about cardiovascular strategy
Novartis's experimental drug pelacarsen, which targets lipoprotein(a) (Lp(a)), a genetic cardiovascular risk factor, failed to reduce serious outcomes in a Phase 3 trial. The study, revealed at the American Heart Association's scientific sessions, showed the drug lowered Lp(a) levels but did not decrease heart attacks, strokes, or deaths over nearly five years. This raises questions about Novartis's cardiovascular strategy.
How this was made
The 30-second read
Why it matters
Novartis' failure may shift capital toward competitors with different mechanisms or later‑stage data.
Market read
First report of a major Phase 3 cardiovascular trial failure; material for biotech and pharma investors.
What to watch
The trial still demonstrated strong Lp(a) lowering, which could support future indications or combination therapies.
Background
Lipoprotein(a) is a genetic risk factor for cardiovascular disease; many companies are developing therapies to lower it.
Ticker impact
Novartis' Phase 3 HORIZON trial of pelacarsen failed to show any reduction in heart attacks, strokes or deaths despite lowering Lp(a).
likely downward pressure as investors price in lack of cardiovascular benefit.
Phase 3 failure is material for a large pharma; market typically reacts negatively to missed efficacy endpoints.
Market effects
may dampen enthusiasm for Lp(a)-lowering therapies across biotech sector.
potential modest impact on European and US pharma indices.
high relevance for investors tracking cardiovascular drug pipelines.
Counterpoint
Some investors may view the Lp(a) reduction as a long‑term asset despite short‑term outcome.
Key entities
- companyNovartis
Swiss pharmaceutical giant conducting the HORIZON trial.
- drugPelacarsen
Experimental Lp(a)-lowering therapy.
